HIGR
Hi-Great Group Holding Company0.2280
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
23.37MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
10-Q
Q2 FY2025 results
Hi-Great Group Holding reported Q2 FY2025 sales of $10,135, down 33.7% y/y from $15,280, while six-month revenue fell 21.8% y/y to $19,018 amid its development-stage pivot to KRAS gene licensing and herbal supplements. Gross profit shrank to $5,531 in the quarter from $7,380 y/y, with operating expenses trimming to $22,575 from $26,743, yielding a narrower operating loss of $17,044 versus $19,363. Net loss matched the operating figure at $17,044, as minor other income offset interest; YTD net loss widened 25.3% y/y to $35,982 on higher professional fees and G&A. Cash dwindled to $222 by quarter-end from $2,140 at year-start, with operating cash use of $10,871 YTD versus $5,347 generated prior year, and stockholders' deficit deepened to $196,710. No non-GAAP metrics disclosed in the 10-Q. Ongoing COVID-19 disruptions pose a lingering threat to operations.
10-Q
Q1 FY2025 results
Hi-Great Group Holding dipped slightly in Q1 FY2025, with sales at $8,883, down 1.8% y/y from $9,050, while gross profit shrank to $1,382 from $4,178 due to higher royalty costs to related party SellaCare. Operating expenses climbed to $20,758 from $14,987, driven by professional fees and G&A, yielding an operating loss of $19,376 versus $10,809 last year; net loss widened to $18,938, with the gap to operating loss under 3% from minor interest income. Cash drained to $207 from $2,140, reflecting $8,387 used in operations, no capex for FCF calculation, and related-party lease obligations settled. No debt burdens, but stockholders' deficit hit $182,166. Development-stage woes persist. COVID-19 lingers as a drag.
10-K
FY2024 results
Hi-Great Group Holding Company posted FY2024 revenue of $69,210, down 37% y/y from $109,491, with gross profit shrinking to $33,968 amid higher royalty costs to related party SellaCare; yet the net loss narrowed to $48,616 from $121,758, thanks to slashed professional fees and G&A. Q4 momentum showed sequential improvement, as operating cash flow turned positive at $16,127 for the year (derived from adjustments including inventory buildup), signaling better liquidity with cash at $2,140 by year-end. Inventory swelled to $76,150, hinting at ramp-up for agritourism and supplements. No dividends or buybacks; related-party lease expires March 2025. Cybersecurity threats loom large, potentially disrupting data management and quarterly operations.
8-K
DTC eligibility approved
Hi-Great Group Holding Company announced on December 12, 2024, that its application to deposit shares with the Depository Trust Company was approved, enabling electronic book-entry deposits. This upgrade allows eligible shareholders to transfer shares digitally for trading, streamlining the process. DTC eligibility boosts liquidity. Yet, shareholders must meet specific criteria to participate.
AAGH
America Great Health
0.00+0.00
BHST
BioHarvest Sciences Inc.
5.50+0.30
ESGH
ESG Inc.
4.40-0.98
GWLL
GOLDENWELL BIOTECH INC
3.00+0.00
HAFG
HOLISTIC ASSET FINANCE GROUP CO
0.55+0.00
HAIN
The Hain Celestial Group, Inc.
1.11-0.06
HFFG
HF Foods Group Inc.
2.56-0.05
HLF
Herbalife Ltd.
14.45-0.45
NATR
Nature's Sunshine Products, Inc
22.38-0.85
USNA
USANA Health Sciences, Inc.
20.33+0.01